Legend Biotech Corp shares rose nearly 30% after its experimental in vivo cell therapy showed efficacy in 12 blood cancer patients. The trial data reported on June 2 marks a shift from traditional CAR-T methods that require complex external cell modification. This simplified delivery method could make Legend Biotech a prime acquisition target for larger pharmaceutical players.

Clinical Success in Blood Cancer Trial